Odronextamab
odronextamab
PHASE3
Drug Profile
ModalityBispecific antibody
RouteIV
Therapy AreaOncology
Peak Sales Est$2000M
Formulations[]
Mechanism: CD20xCD3 bispecific
Expert: Bispecific T-cell engager binding CD20 on B-cells and CD3 on T-cells, inducing T-cell mediated cytotoxicity.
Everyday: A protein that helps immune cells find and kill lymphoma cells.
Targets: ["CD20","CD3"]
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| R/R DLBCL 3L+ | PHASE3 | Odronextamab Ph3 in DLBCL | [] |
| R/R FL 3L+ | PHASE3 | Odronextamab Ph3 in FL | [] |
Upcoming Catalysts (1)
Odronextamab - R/R FL - Ph3 Topline
2026-2027
Notes
CD20xCD3 bispecific T-cell engager for B-cell NHL. Competes with mosunetuzumab (Roche/Lunsumio), glofitamab (Roche/Columvi), epcoritamab (AbbVie/Genmab/Tepkinly). Ph1/2 showed strong ORR in R/R FL (80%) and R/R DLBCL (49%). Two Ph3 studies ongoing.
Data from Supabase · Updated 2026-03-24